 Shares of Relmada Therapeutics Inc. RLMD, -0.95 tumbled about 40 in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint in a Phase 3 clinical trial. The stock closed Wednesday at 4.16, a three-year low. 